Intravenous iron is a standard treatment for patients undergoing hemodialysis, but comparative data regarding clinically effective regimens are limited.
T h e ne w e ngl a nd jou r na l o f m e dicine P atients undergoing maintenance hemodialysis usually have a negative iron balance owing to reduced absorption and increased blood loss. 1 The intravenous administration of iron has become standard care in the management of anemia, and large doses are increasingly used to reduce exposure to erythropoiesis-stimulating agents 2, 3 in order to reduce costs and mitigate concerns about potential risks, particularly because of cardiovascular toxic effects that have been observed in trials. [4] [5] [6] [7] [8] However, intravenous iron therapy may cause harm by increasing the risks of infection, oxidative stress, vascular calcification, and atherothrombosis. [9] [10] [11] [12] [13] Rigorous scientific evaluation of the use of high doses of iron in patients undergoing hemodialysis has been limited, which has resulted in marked variation in its use among individual practitioners and across countries. 3 We assessed first the noninferiority, and then the safety and efficacy, of a high-dose regimen of intravenous iron administered proactively, as compared with a low-dose regimen of intravenous iron administered reactively, in patients undergoing hemodialysis in the Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL) trial.
Me thods

Trial Design and Oversight
We conducted this prospective, randomized, openlabel, blinded end-point, 14 controlled trial at 50 sites in the United Kingdom. The trial protocol 15 (available with the full text of this article at NEJM.org) was approved by the relevant health authorities and institutional review boards, and all the patients provided written informed consent. An independent data and safety monitoring committee performed regular safety surveillance. Data were entered into an electronic case-report form by the investigators (see the Supplementary Appendix, available at NEJM.org) and were analyzed at the Robertson Centre for Biostatistics, University of Glasgow, in the United Kingdom.
This was an academic investigator-led trial. The trial was funded by Kidney Research UK, which was supported by an unrestricted grant from Vifor Fresenius Medical Care Renal Pharma (which also provided iron sucrose for the trial, free of charge). Vifor Fresenius Medical Care Renal Pharma had no input into the trial design or the data collection or analysis. However, the company was kept abreast of the progress of the trial by regular study reports and newsletters. No confidentiality agreements regarding the data were in place.
The initial draft of the manuscript was written by the first author and revised by all the authors. Medical writing assistance was provided by a professional medical writer, funded by Kidney Research UK (supported by Vifor Fresenius Medical Care Renal Pharma). The authors had access to the final trial results and take responsibility for the accuracy and completeness of the data, for the fidelity of the trial to the protocol, and for the decision to submit the manuscript for publication.
Participants
Adults with end-stage kidney disease in whom maintenance hemodialysis had been initiated no more than 12 months before the initial screening visit, who had a ferritin concentration of less than 400 μg per liter and a transferrin saturation of less than 30%, and who were receiving an erythropoiesis-stimulating agent were eligible to participate. Any iron therapy that had been prescribed previously was discontinued at the screening visit. The full eligibility criteria are provided in the protocol.
Randomization, Treatment, and Follow-up
Using a Web-based randomization system, we randomly assigned participants, in a 1:1 ratio, to receive a regimen of high-dose intravenous iron administered proactively or a regimen of lowdose intravenous iron administered reactively; patients were then evaluated monthly. Randomization was stratified according to vascular access (dialysis catheter vs. arteriovenous fistula or graft), diagnosis of diabetes (yes vs. no), and duration of hemodialysis treatment (<5 months vs. ≥5 months).
The ferritin concentration and transferrin saturation were measured monthly (usually during the first week of the month), and these values determined the monthly dose of iron sucrose to be administered intravenously during the subsequent week of hemodialysis (usually the second week of the month). In the high-dose group, 400 mg of iron sucrose per month, to be administered intravenously, was prescribed to the patients, with safety cutoff limits (ferritin concentration of 700 μg per liter or a transferrin saturation of 40%) above which further intravenous iron ad-Intr avenous Iron in Patients Undergoing Hemodialysis ministration was withheld pending repeat testing 1 month later. Patients in the low-dose group received a monthly dose of 0 mg to 400 mg of iron sucrose as required to maintain a minimum target ferritin concentration of 200 μg per liter and a transferrin saturation of 20%, in line with accepted clinical guidelines (for details of the iron-dosing regimen, see the Supplementary Appendix). Iron therapy was temporarily withheld if the trial team identified an active infection that was deemed by the investigator to be sufficient to contraindicate the use of intravenous iron. Therapy was restarted when it was judged by the investigator to be safe to do so.
Clinicians selected the dose of erythropoiesisstimulating agent that would be sufficient to maintain a hemoglobin level of 10 to 12 g per deciliter.
16 Apart from the dose of erythropoiesisstimulating agent, the trial teams treated patients according to standard practice.
Trial End Points
The primary end point was the composite of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or death from any cause, assessed in a time-to-first-event analysis; definitions of the end-point events are provided in the Supplementary Appendix. The first secondary end point consisted of the components of the primary end point, including first and repeat events, which were analyzed as recurrent events. Other secondary efficacy end points included death from any cause; the composite of fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, or hospitalization for heart failure; and each of the three subcomponents of that end point, all assessed in time-to-first-event analyses. An independent committee whose members were unaware of the trial-group assignments adjudicated these events according to prespecified criteria. Additional secondary efficacy end points included the dose of erythropoiesis-stimulating agent, the incidence of blood transfusion, and two quality-of-life measures (the European Quality of Life-5 Dimensions [EQ-5D] questionnaire and the Kidney Disease Quality of Life instrument).
Safety end points included vascular access thrombosis, hospitalization for any cause, and hospitalization for infection, each assessed in a time-to-first-event analysis, and the rate of episodes of infection. Laboratory tests, including the hemoglobin level, serum ferritin concentration, and transferrin saturation, were assessed monthly. Data on serious adverse events were collected prospectively, and events were coded with the use of the Medical Dictionary for Regulatory Activities (MedDRA), version 15.1. Data on nonserious adverse events, other than infection and vascular access thrombosis, were not collected.
Statistical Analysis
In the initial sample-size calculations, we assumed a 3-year event rate of 40% in the low-dose group and a 10% loss to follow-up (including loss to follow-up due to kidney transplantation). Thus, we estimated that a sample of 2080 patients who had 631 primary end-point events would provide the trial with 80% power to assess the noninferiority of high-dose iron to lowdose iron, with a noninferiority limit for the hazard ratio of 1.25.
Summary statistics are provided as numbers and percentages, as mean values with standard deviations, and as median values with interquartile ranges (25th to 75th percentile). Treatment effects were estimated as the effect in the highdose group as compared with (or minus) the effect in the low-dose group, with adjustment for the stratification variables at randomization. The primary end point was analyzed first in terms of noninferiority in the intention-to-treat population, which included all the patients who had undergone randomization validly, with a supporting analysis in a per-protocol population that excluded patients with a major protocol violation. Analyses were censored at the date of kidney transplantation, withdrawal of consent, loss to follow-up, or transfer to home or peritoneal dialysis, whichever came first. Noninferiority was also assessed in a sensitivity analysis that included only patients who were currently receiving treatment, with data censored after patients discontinued the trial drug. The time-to-firstevent analyses were conducted with the use of cause-specific Cox proportional-hazards models, including the stratification variables and the treatment variable. The noninferiority analysis tested the null hypothesis that the hazard ratio for the treatment effect was at least 1.25 against the alternative that the hazard ratio was less than 1.25, with a required one-sided significance level of 0.025. If noninferiority was established, a twosided superiority test (Wald statistic) was carried out with no penalty regarding the P value.
The incidence of death from any cause and a
T h e ne w e ngl a nd jou r na l o f m e dicine * Plus-minus values are means ±SD. There were no significant differences between the two groups except for smoking status (P = 0.03) and the hemoglobin level (P = 0.04). Percentages may not total 100 because of rounding. IQR denotes interquartile range (25th to 75th percentile). † Race was reported by the patients. ‡ The body-mass index is the weight in kilograms divided by the square of the height in meters. § Blood-pressure measurements were taken before hemodialysis. ¶ For darbepoetin alfa and methoxy polyethylene glycol-epoetin beta, the weekly reported dose was multiplied by 200 to convert the units from micrograms to international units. ‖ Tubulointerstitial disease included pyelonephritis, reflux nephropathy, and obstructive uropathy. composite of myocardial infarction, stroke, or hospitalization for heart failure as recurrent events was analyzed with the use of the proportional-means model of Lin et al. 17 and described in the form of mean frequency functions (method of Ghosh and Lin) . 18 Other statistical methods and details regarding statistical assumptions are described in the Supplementary Appendix. The results for the secondary end points are reported as point estimates and 95% confidence intervals with no adjustment for multiple comparisons, so the confidence intervals should not be used to infer definitive treatment effects. The cumulative doses of intravenous iron were compared between the treatment groups with the use of Wilcoxon rank-sum tests. The statistical analysis plan is available with the protocol at NEJM.org.
R esult s
Patients
The trial was conducted from November 2013 to June 2018. Of the 2589 patients who were screened for entry into the trial, 448 did not meet the criteria for randomization. A total of 2141 patients were randomly assigned to a treatment group (1093 patients to the high-dose group and 1048 to the low-dose group) and constituted the intention-to-treat population (Fig. S1 in the Supplementary Appendix). Followup continued until June 6, 2018.
The characteristics of the patients at baseline were generally well balanced between the two treatment groups, except for smoking status (P = 0.03) and the hemoglobin level (P = 0.04) ( Table 1 ). The prevalence of cardiovascular disease (a history of one or more of the following: myocardial infarction, stroke, heart failure, atrial fibrillation, or peripheral vascular disease) was 29.6% in the high-dose group and 28.2% in the low-dose group. With the exception of angiotensin-converting-enzyme inhibitors or angiotensinreceptor blockers and phosphate binders, the use of medications at baseline was similar in the two groups (Table S1 in the Supplementary Appendix). The mean cumulative doses of intravenous iron that were received by the patients in the two treatment groups are shown over time. Data plotted at month 0 represent the first administration of iron after randomization. At all the time points, patients in the group that received high-dose iron proactively received greater cumulative doses of iron than did the patients in the group that received low-dose iron reactively (P<0.001 for all time points). The cumulative doses of iron were compared between the treatment groups with the Wilcoxon rank-sum test. I bars indicate 95% confidence intervals. Excluding patients who died or underwent kidney transplantation, follow-up was incomplete for 162 patients (14.8%) in the high-dose group and for 175 (16.7%) in the low-dose group (Fig.  S1 in the Supplementary Appendix). The median follow-up was 2.1 years, with a maximum followup of 4.4 years.
Doses of Iron and ErythropoiesisStimulating Agents
The cumulative doses of intravenous iron were greater in the high-dose group than in the lowdose group (Fig. 1) . At month 12, the patients in the high-dose group had received a median of 2000 mg (95% confidence interval [CI], 1900 to 2100) more iron than the patients in the lowdose group. The median monthly dose of iron was 264 mg (interquartile range, 200 to 336) in the high-dose group and 145 mg (interquartile range, 100 to 190) in the low-dose group; the median difference in the monthly iron dose was 121 mg (95% CI, 114 to 129). The ferritin concentrations and transferrin saturation both increased from baseline rapidly with the high-dose regimen, as compared with the low-dose regimen (Figs. S2 and S3 in the Supplementary Appendix).
The cumulative dose of erythropoiesis-stimulating agent was lower in the high-dose group than in the low-dose group at all the postbaseline time points examined through 36 months (Fig. S4 in the Supplementary Appendix) . The median monthly dose of erythropoiesis-stimulating agent was 19.4% lower in patients receiving the high-dose regimen (29,757 IU per month; interquartile range, 18,673 to 48,833) than in patients receiving the low-dose regimen (38,805 IU per month; interquartile range, 24,377 to 60,620) (median difference, −7539 IU per month; 95% CI, −9485 to −5582) ( Table 2 ). Although patients in the two treatment groups had increases from baseline in the hemoglobin level over time, more rapid increases were observed in the high-dose group than in the low-dose group (Fig. S5 in the Supplementary Appendix). Plots of the median values and interquartile ranges of the abovementioned laboratory tests are shown in Figures S6 through S10 in the Supplementary Appendix.
Primary End Point
A primary end-point event occurred in 320 patients (29.3%) in the high-dose group, as compared with 338 (32.3%) in the low-dose group * All the analyses were conducted in the intention-to-treat population and are superiority analyses unless indicated otherwise. The widths of the confidence intervals for the secondary end points have not been adjusted for multiple comparisons, so the confidence intervals should not be used to infer definitive treatment effects. The estimated treatment effects are hazard ratios unless indicated otherwise. NA denotes not available. † The primary end point was a composite of death from any cause, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. ‡ The P value is for noninferiority. In the primary end-point analysis in the intention-to-treat and per-protocol populations, P = 0.04 for superiority. § The treatment effect is a rate ratio. ¶ For darbepoetin alfa and methoxy polyethylene glycol-epoetin beta, the weekly reported dose was multiplied by 200 to convert the units from micrograms to international units. The treatment effect is the estimated difference between the group medians.
‖ It was not possible to calculate a corresponding confidence interval for the number of units of blood transfused because of the high percentage of patients without an event. ** Plus-minus values for the least-squares mean change in scores are means with the standard error. The treatment effect is the estimated difference in the mean changes from baseline in the treatment groups as calculated with the use of a mixed-effects repeated-measures model. Scores on the European Quality of Life-5 Dimensions (EQ-5D) quality-of-life health index range from −0.594 to 1.0, with higher scores indicating better quality of life. The EQ-5D analysis included data from 783 patients in the high-dose group and from 749 in the lowdose group. † † Plus-minus values for the least-squares mean change in scores are means with the standard error. The treatment effect is the estimated difference in the mean changes from baseline in the treatment groups as calculated with the use of a mixed-effects repeated-measures model. Scores on the Kidney Disease Quality of Life (KDQOL) instrument range from 0 to 100, with higher scores indicating better quality of life. The KDQOL analysis included data from 790 patients in the high-dose group and from 755 in the low-dose group.
T h e ne w e ngl a nd jou r na l o f m e dicine (hazard ratio, 0.85; 95% CI, 0.73 to 1.00; P<0.001 for noninferiority; P = 0.04 for superiority) ( Fig. 2A and Table 2 ). Results were similar in the per-protocol population (hazard ratio, 0.85; 95% CI, 0.73 to 0.99; P<0.001 for noninferiority; P = 0.04 for superiority). The effect of high-dose iron therapy on the primary end point was consistent across all the prespecified subgroups (vascular access, diabetes status, and duration of dialysis treatment), with no significant interactions observed (Fig. S11 in the Supplementary Appendix).
Secondary Efficacy End Points
There were 246 deaths (22.5% of the patients) in the high-dose group and 269 (25.7%) in the lowdose group (hazard ratio, 0.84; 95% CI, 0.71 to 1.00) (Fig. 2B and Table 2 ), with consistent results observed across the prespecified subgroups (Fig.  S11 in the Supplementary Appendix). The rate of the composite of fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, or hospitalization for heart failure was lower in the highdose group than in the low-dose group (hazard ratio, 0.80; 95% CI, 0.64 to 1.00). Similarly, the rates of the individual components of fatal or nonfatal myocardial infarction and hospitalization for heart failure were lower among patients receiving high-dose iron than among those receiving low-dose iron ( Table 2 ). The rate of stroke was similar in the two treatment groups. Death and a composite of myocardial infarction, stroke, or hospitalization for heart failure as recurrent events occurred at a rate of 19.4 events Panel A shows the cumulative event rates for the primary efficacy end point (a composite of death from any cause, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure). Panel B shows the rates of death from any cause, and Panel C shows the rates of death from any cause and a composite of myocardial infarction, stroke, and hospitalization for heart failure as recurrent events plotted in the form of mean frequency functions with the use of the method of Ghosh and Lin. 18 The hazard ratios (with 95% confidence intervals) and rate ratio (with the 95% confidence interval) were adjusted for the baseline stratification variables of vascular access, diabetes status, and duration of dialysis treatment.
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per 100 patient-years in the high-dose group, as compared with 24.6 events per 100 patient-years in the low-dose group (rate ratio, 0.77; 95% CI, 0.66 to 0.92) (Fig. 2C and Table 2 ). Patients in the high-dose group were less likely to receive blood transfusions than those in the low-dose group (hazard ratio, 0.79; 95% CI, 0.65 to 0.95). There were no significant between-group differences with regard to changes from baseline in either the EQ-5D quality-of-life health index or the Kidney Disease Quality of Life overall score.
Safety
Vascular access thrombosis occurred in 262 patients (24.0%) in the high-dose group and in 218 (20.8%) in the low-dose group. The rates of hospitalization for any cause and for infection were similar in the two treatment groups ( Table 2) . The rate of all episodes of infection in the highdose group was 63.3 events per 100 patient-years, as compared with 69.4 events per 100 patientyears in the low-dose group (rate ratio, 0.91; 95% CI, 0.79 to 1.05).
Serious adverse events occurred in 709 patients (64.9%) in the high-dose group and in 671 (64.0%) in the low-dose group. The rates of the most common serious adverse events, analyzed according to MedDRA system organ class, were generally similar in the two treatment groups (Table 3) . Infection was the most common noncardiovascular cause of death, and the rates were similar in the two treatment groups (Table S2 in the Supplementary Appendix).
Other End Points
High-dose iron administered proactively was associated with a small decrease in the platelet count over time, as compared with a small increase in the group that received low-dose iron administered reactively (Figs. S12 and S13 in the Supplementary Appendix). No significant between-group differences were observed with regard to the serum albumin concentration (Figs. S14 and S15 in the Supplementary Appendix).
Discussion
In contrast to results from observational studies, [19] [20] [21] [22] [23] [24] the results of this trial showed that the use of a high-dose intravenous iron regimen administered proactively was superior to the use of a low-dose intravenous iron regimen administered reactively and was associated with a lower risk of death or major adverse cardiovascular events. Patients who had been assigned to receive high-dose iron therapy were less likely to have a myocardial infarction or be hospitalized for heart failure than those who had been assigned to receive low-dose iron therapy. In addition, high-dose iron administered proactively appeared to protect against recurrent events. Although iron therapy has been associated with a lower risk of cardiovascular events in placebo-controlled trials involving patients with heart failure, 25-28 such benefits have not been observed in an incident dialysis population (with a baseline prevalence of heart failure of <5%). Furthermore, patients who received high-dose iron therapy had fewer blood transfusions and received lower doses of erythropoiesis-stimulating agents to maintain target hemoglobin levels than those in the low-dose group; patients in the high-dose group also had a faster increase in the hemoglobin level.
The cardiovascular safety profile that is associated with the use of high-dose intravenous iron therapy to maintain a target hemoglobin level is notable, given the safety concerns about using higher doses of erythropoiesis-stimulating agents to elevate the hemoglobin level. We speculate that the dose-sparing effect of intravenous iron therapy on erythropoiesis-stimulating agents might contribute to the cardiovascular profile of highdose iron therapy that was observed in this trial. It is also possible that iron replacement in patients with iron deficiency has direct cardiovascular benefits.
The absence of a greater risk of infection with the proactive, high-dose intravenous iron regimen is important, given studies that have suggested that iron might potentiate bacterial growth and infection. 12, [29] [30] [31] [32] In our trial, the investigators were advised to discontinue iron therapy in patients during episodes of infection.
The most appropriate intravenous iron-replacement regimen in adults undergoing dialysis is unknown, which has resulted in different local, national, and international recommendations and practices. Observational studies have raised concern that monthly doses of 300 mg or more of intravenous iron are associated with poor outcomes. [19] [20] [21] In the high-dose group of our trial, we used a monthly dose of 400 mg, with a per-T h e ne w e ngl a nd jou r na l o f m e dicine protocol temporary discontinuation of treatment only if the ferritin concentration exceeded 700 μg per liter or the transferrin saturation was 40% or higher. Patients in the high-dose group received approximately twice the amount of iron as those in the low-dose group over the first year of the trial and 83.5% more iron per month over the course of the trial. The median monthly dose of iron that was administered in the high-dose group was 264 mg, which is greater than the approximately 218-mg dose that was reported by the Dialysis Outcomes and Practice Patterns Study in the United States. 33 Given the improved outcomes that were observed with the high-dose intravenous iron regimen in our trial, the safety and efficacy of even higher doses of iron might be explored in further trials.
The strengths of our trial include its size and Endocrine disorder 1 (0.1) 0 * Data are the numbers and percentages of patients who had a serious adverse event, according to Medical Dictionary for Regulatory Activities, version 15.1, system organ class. † Investigation was defined as results of a laboratory test or other medical investigation that met the requirements for a serious adverse event. ‡ Social circumstance was defined as an event of medical relevance to the evaluation of other data (e.g., hospitalization for social reasons, such as general deterioration in health that led to an inability to function at home). Table 3 . Serious Adverse Events.* long duration of follow-up, the collection and adjudication of important clinical events, and the limited exclusion criteria that allowed for the enrollment of a cohort of patients representative of those seen in routine clinical practice. Limitations of the trial include the restriction of the trial sites to a single country. Thus, the generalizability of the trial findings to dialysis populations worldwide is unclear. The open-label nature of the trial may have potentially biased the rates of blood transfusion. Ongoing iron losses that have been associated with hemodialysis, combined with the iron-storage capacity of the reticuloendothelial system and the withholding of iron in patients with markedly elevated iron indexes (ferritin concentration of >700 μg per liter or transferrin saturation of ≥40%), were expected to reduce the risk of overt toxic effects of iron in this population. 1 However, the safety of this high-dose iron regimen cannot be confirmed beyond the duration of the current trial. Finally, because quality-of-life data were missing for many patients, the interpretation of the effect of the iron dose with regard to these end points is limited.
In conclusion, this trial showed that, among patients undergoing hemodialysis, the use of a high-dose regimen of intravenous iron administered proactively resulted in a significantly lower risk of death or major nonfatal cardiovascular events as compared with that observed with a reactive, low-dose regimen. This dosing strategy also resulted in a significantly lower dose of erythropoiesis-stimulating agent and a lower incidence of blood transfusion, whereas the incidence of infection and hospitalization for any cause did not differ significantly between the two treatment groups.
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